3 results
Primary objective:The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.Secondary…
In this study, we look at how safe the new medicinal product XMT-1536 is for the treatment of ovarian cancer and how well it works. We compare the effect of XMT-1536 with the effect of a placebo. A placebo is a product without the active ingredient…
Primary Objective: This study will evaluate the efficacy, safety, and pharmacokinetics of RO7247669 plus nab-paclitaxel compared with pembrolizumab plus nab-paclitaxel in patients with previously untreated, locally advanced, unresectable or…